VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)
Titel:
VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)
Auteur:
Fasching, P.A. Slamon, D. Nowecki, Z. Kukielka-Budny, B.D. Stroyakovskiy, D. Yardley, D. Huang, C. Chan, A. Chia, S. Martin, M. Rugo, H.S. Loi, S. Hurvitz, S.A. Untch, M. Afenjar, K. Fresco, R. Danyliv, A. Ferrusi, I. Li, Z. Hortobagyi, G.N.